These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7977435)

  • 21. Reversible defect in antigen-induced lymphokine and gamma-interferon generation in cutaneous leishmaniasis.
    Murray HW; Rubin BY; Carriero S; Acosta AM
    J Immunol; 1984 Oct; 133(4):2250-4. PubMed ID: 6432909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.
    Suárez-Méndez R; García-García I; Fernández-Olivera N; Valdés-Quintana M; Milanés-Virelles MT; Carbonell D; Machado-Molina D; Valenzuela-Silva CM; López-Saura PA
    BMC Infect Dis; 2004 Oct; 4():44. PubMed ID: 15500691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biological properties and clinical applications of interferon gamma (IFN-gamma)].
    Robak T
    Acta Haematol Pol; 1994; 25(1):19-29. PubMed ID: 8209610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection.
    Belosevic M; Davis CE; Meltzer MS; Nacy CA
    J Immunol; 1988 Aug; 141(3):890-6. PubMed ID: 3135315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunomodulatory effects of interferon-gamma on autoreactive nephritogenic T-cell clones.
    Meyers CM; Zhang Y
    Kidney Int; 1999 Apr; 55(4):1395-406. PubMed ID: 10201004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of treatment with interferon-gamma alone in visceral leishmaniasis.
    Sundar S; Murray HW
    J Infect Dis; 1995 Dec; 172(6):1627-9. PubMed ID: 7594733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokines as antimicrobial therapy for the T cell-deficient patient: prospects for treatment of nonviral opportunistic infections.
    Murray HW
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S407-13. PubMed ID: 8274606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
    Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
    PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of interferon-gamma treatment on surgically simulated wound infection in mice.
    Hershman MJ; Sonnenfeld G; Mays BW; Fleming F; Trachtenberg LS; Polk HC
    Microb Pathog; 1988 Feb; 4(2):165-8. PubMed ID: 3143895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mycobacterium avium-induced SOCS contributes to resistance to IFN-gamma-mediated mycobactericidal activity in human macrophages.
    Vázquez N; Greenwell-Wild T; Rekka S; Orenstein JM; Wahl SM
    J Leukoc Biol; 2006 Nov; 80(5):1136-44. PubMed ID: 16943387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posttranscriptional inhibition of gene expression by Mycobacterium tuberculosis offsets transcriptional synergism with IFN-gamma and posttranscriptional up-regulation by IFN-gamma.
    Qiao Y; Prabhakar S; Canova A; Hoshino Y; Weiden M; Pine R
    J Immunol; 2004 Mar; 172(5):2935-43. PubMed ID: 14978096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A therapeutic trial of experimental tuberculosis with gamma-interferon in an immunocompromised mouse model].
    Kawakami K; Teruya K; Tohyama M; Kudeken N; Saito A
    Kekkaku; 1994 Oct; 69(10):607-13. PubMed ID: 7799571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony.
    Murray HW; Berman JD; Wright SD
    J Infect Dis; 1988 May; 157(5):973-8. PubMed ID: 2834469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity.
    Mody CH; Tyler CL; Sitrin RG; Jackson C; Toews GB
    Am J Respir Cell Mol Biol; 1991 Jul; 5(1):19-26. PubMed ID: 1908686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice.
    Doherty TM; Sher A
    J Immunol; 1998 Jun; 160(11):5428-35. PubMed ID: 9605144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease.
    Bemiller LS; Roberts DH; Starko KM; Curnutte JT
    Blood Cells Mol Dis; 1995; 21(3):239-47. PubMed ID: 8673477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transient transgenic expression of gamma interferon promotes Legionella pneumophila clearance in immunocompetent hosts.
    Deng JC; Tateda K; Zeng X; Standiford TJ
    Infect Immun; 2001 Oct; 69(10):6382-90. PubMed ID: 11553582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response.
    Squires KE; Schreiber RD; McElrath MJ; Rubin BY; Anderson SL; Murray HW
    J Immunol; 1989 Dec; 143(12):4244-9. PubMed ID: 2512353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-gamma in the management of infectious diseases.
    Gallin JI; Farber JM; Holland SM; Nutman TB
    Ann Intern Med; 1995 Aug; 123(3):216-24. PubMed ID: 7598304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.